Physician profile
Katrina Kerns
NPI 1003063561
$627.97
in general payments reported to CMS, 2019-2025
15 companies · $87.56 in 2025
The $87.56 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $77.26 · 2021: $48.90 · 2022: $136 · 2023: $97.88 · 2024: $70.44 · 2025: $87.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $255.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $139.77 | 2019-2023 | |
| Corium, LLC | $115.83 | 2021-2024 | Azstarys |
| Cranial Technologies, INC | $59.60 | 2019-2023 | Doc Band |
| Dermira, INC. | $41.29 | 2019-2020 | |
| Sanofi Pasteur INC. | $40.30 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $39.94 | 2025 | |
| Ironshore Pharmaceuticals INC. | $37.23 | 2022-2023 | Jornay Pm |
| Vertical Pharmaceuticals, LLC | $28.10 | 2019-2024 | Relexxii |
| Glaxosmithkline, LLC. | $24.36 | 2019-2022 | |
| Shire North American Group INC | $20.61 | 2019 | |
| Pfizer INC. | $18.77 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.69 | 2021 | |
| Supernus Pharmaceuticals, INC. | $15.63 | 2024 | Qelbree |
| Cipher Pharmaceuticals US LLC | $14.86 | 2025 | Spinosad, Natroba |
| Azurity Pharmaceuticals, INC. | $13.99 | 2025 | Alvesco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katrina Kerns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.